Sionna Therapeutics (NASDAQ:SION) Lowered to Strong Sell Rating by Wall Street Zen

Key Points

• Wall Street Zen downgraded Sionna Therapeutics to “strong sell” from “sell,” while broader analyst sentiment remains “hold,” with 11 holds, one buy and one sell.
• SION opened at $6.46, far below its 52-week high of $54.97, and the company reported a quarterly loss of $0.66 per share, missing estimates by $0.02.
• Insiders sold 403,726 shares worth approximately $18.3 million over the past 90 days, although several institutional investors recently increased their positions.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) was downgraded by Wall Street Zen from a "sell" rating to a "strong sell" rating in a report issued on Saturday.

SION has been the subject of several other reports. BTIG Research downgraded Sionna Therapeutics from a "buy" rating to a "neutral" rating in a report on Monday, August 10th. Royal Bank Of Canada upgraded Sionna Therapeutics from an "underperform" rating to a "sector perform" rating and set a $5.00 price target on the stock in a research note on Monday, August 10th. Raymond James Financial cut Sionna Therapeutics from a "strong-buy" rating to a "market perform" rating in a research report on Monday, August 10th. Stifel Nicolaus reissued a "hold" rating and issued a $7.00 target price on shares of Sionna Therapeutics in a research report on Monday, August 10th. Finally, JonesTrading lowered shares of Sionna Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 10th. One investment analyst has rated the stock with a Buy rating, eleven have issued a Hold rating and one has assigned a Sell rating to the company's stock. According to data from MarketBeat, Sionna Therapeutics currently has a consensus rating of "Hold" and a consensus price target of $42.22.

Sionna Therapeutics Price Performance

NASDAQ:SION opened at $6.46 on Friday. The company's 50-day simple moving average is $39.18 and its 200 day simple moving average is $39.18. Sionna Therapeutics has a one year low of $4.01 and a one year high of $54.97. The firm has a market capitalization of $292.07 million, a P/E ratio of -2.96 and a beta of 1.33.

Sionna Therapeutics (NASDAQ:SION - Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.64) by ($0.02). On average, equities research analysts expect that Sionna Therapeutics will post -2.55 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Peter A. Thompson sold 85,918 shares of the stock in a transaction that occurred on Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the completion of the transaction, the director directly owned 2,469,959 shares of the company's stock, valued at approximately $110,802,360.74. This represents a 3.36% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Orbimed Advisors Llc sold 85,918 shares of the firm's stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $44.86, for a total value of $3,854,281.48. Following the transaction, the director owned 2,469,959 shares of the company's stock, valued at $110,802,360.74. This represents a 3.36% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 403,726 shares of company stock worth $18,259,354 over the last ninety days. Insiders own 5.10% of the company's stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Deutsche Bank AG increased its position in Sionna Therapeutics by 4.5% in the fourth quarter. Deutsche Bank AG now owns 10,029 shares of the company's stock worth $413,000 after purchasing an additional 433 shares during the last quarter. Bank of America Corp DE lifted its position in Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company's stock valued at $192,000 after purchasing an additional 529 shares during the last quarter. MetLife Investment Management LLC lifted its position in Sionna Therapeutics by 6.6% during the fourth quarter. MetLife Investment Management LLC now owns 8,565 shares of the company's stock valued at $352,000 after purchasing an additional 532 shares during the last quarter. BNP Paribas Financial Markets grew its stake in shares of Sionna Therapeutics by 35.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company's stock worth $70,000 after buying an additional 619 shares in the last quarter. Finally, State of Wyoming bought a new stake in shares of Sionna Therapeutics in the 2nd quarter worth about $35,000.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source